TEST:

Immune Profile Score Algorithmic Test

The Immune Profile Score (IPS) algorithmic test, which is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic solid tumors who are already considered candidates for immune checkpoint inhibitor–based therapy, is now available for clinical use. The IPS model was developed via a machine-learning framework featuring tumor mutational burden and 8 RNA-based biomarkers. By factoring in a combination of immunotherapy-related biomarkers derived from DNA and RNA test results, IPS score is calculated on a scale of 0 to 100, which determines classification as IPS-high or IPS-low.